The publicly traded company Predictive Oncology will raise $344.4 million to launch the ATH token treasury strategy

ChainCatcher news, according to GlobeNewswire, medical device company Predictive Oncology Inc. (NASDAQ: POAI) today announced the pricing of two private placement financing transactions to support the implementation of its digital asset portfolio strategy, with the core holding asset being the native functional token ATH of the Aethir ecosystem.

The company will raise approximately $344.4 million through two private investment in public equity (PIPE) financings for the purchase and sale of common stock and pre-funded warrants:

Cash PIPE: The company will issue approximately 66.7 million shares of common stock (or common stock in lieu of pre-funded warrants) at an issue price of $0.7751 per share, with total cash gross proceeds of approximately $51.7 million.

Crypto PIPE: The company will issue up to 223.6 million pre-funded warrants, each priced at the issue price minus $0.01, in exchange for approximately $292.7 million in nominal value, equivalent to approximately $173.3 million in discount value, in the form of both locked and unlocked Aethir tokens as physical contributions.

The pre-funded warrants in the Crypto PIPE will be immediately exercisable upon the company's receipt of shareholder approval. The two PIPEs are expected to close simultaneously around October 2, 2025, subject to the satisfaction of customary closing conditions. The company plans to use the physical contributions of Aethir (ATH) to implement the digital asset portfolio strategy and to utilize the remaining net proceeds from the PIPE primarily to acquire ATH in the open market to further support this strategy, as well as for working capital and general corporate purposes.